Item 1A. Risk Factors
Item
1A. Risk Factors.
Factors
that could cause our actual results to differ materially from those in this Quarterly Report include the risk factors described in our
filings with the SEC, including our Annual Report. Additional risk factors not presently known to us or that we currently deem immaterial
may also impair our business or results of operations. We may disclose changes to such factors or disclose additional factors from time
to time in our future filings with the SEC. As of the date of this Quarterly Report on Form 10-Q, there have been no material updates
or changes with respect to the risk factors previously disclosed in our Annual Report, other than as set forth below, which should be
read in conjunction with the risks described in our Annual Report.
Risks
Related to CFO Silvia.
Although
CFO Silvia attempts to remedy any issues it observes in its products as effectively and rapidly as possible, such efforts may not be
timely, may hamper production or may not completely satisfy its customers.
CFO
Silvia has performed, and continues to perform, extensive internal testing on its products and features, though, like the rest of the
industry, it currently has a limited frame of reference by which to evaluate certain aspects of its long-term quality, reliability, durability
and performance characteristics, including exposure to or consequence of external attacks. While CFO Silvia attempts to identify and
address or remedy defects it identifies pre-production and sale, there may be latent defects that it may be unable to detect or control
for in its products, and thereby address, prior to its sale to customers.
Because
the lack of a public market for CFO Silvia’s capital stock made it difficult to evaluate the fair market value of CFO Silvia’s
capital stock, the value of our shares of Common Stock issued to CFO Silvia’s stockholders in connection with the Merger may be
more or less than the fair market value of CFO Silvia’s capital stock.
The
outstanding capital stock of CFO Silvia was privately held and was not traded in any public market. The lack of a public market made
it difficult to determine the fair market value of CFO Silvia’s capital stock. Because the percentage of our equity issued to CFO
Silvia’s stockholders in the Merger was determined based on negotiations between the parties, it is possible that the value of
our shares of Common Stock issued to CFO Silvia’s stockholders in connection with the Merger was more or less than the fair market
value of CFO Silvia’s capital stock.
Risks
Related to the Merger
Our
existing stockholders have reduced ownership and voting interests in ProCap following completion of the Merger.
We
issued 7,516,951 shares of our Common Stock upon completion of the Merger; further, we may issue up to 9,000,000 additional earnout shares
in a five-year period. Based on the number of shares of Common Stock of ProCap outstanding on February 10, 2026, the record date for
our Annual Meeting of Stockholder held on March 27, 2026, upon the completion of the Merger, current ProCap stockholders and former CFO
Silvia stockholders would own approximately 90.3% and 9.7% of our Common Stock, respectively.
When
the Merger occurred, each CFO Silvia stockholder who received shares of our Common Stock became a stockholder of ProCap. As a result,
the percentage ownership of ProCap held by each of the stockholders prior to the Merger was smaller than such stockholder’s percentage
ownership of ProCap prior to the Merger. Our current stockholders will, therefore, have proportionately less ownership and voting interests
in ProCap following the Merger than they had prior to the Merger.
29
We
may fail to realize the anticipated benefits of the Merger.
The
Company believes that there are significant benefits that may be realized by the Merger. However, the efforts to realize these benefits
will be a complex process and may disrupt our existing operations if not implemented in a timely and efficient manner. The full benefits
of the Merger may not be realized as expected or may not be achieved within the anticipated time frame, or at all. Failure to achieve
the anticipated benefits of the Merger could adversely affect our business, operating results or financial condition and cause the combined
business to not perform as expected. Specifically, the following issues, among others, must be addressed to realize the anticipated benefits
of the Merger:
●
combining
certain of the companies’ financial, reporting and corporate functions;
●
consolidating
the companies’ administrative and IT infrastructure;
●
expanding
CFO Silvia’s finance and accounting infrastructure and personnel, including SEC reporting capabilities, technical accounting,
tax, internal audit and compliance capabilities;
●
implementing
and maintaining requisite internal controls over financial reporting and disclosure controls and procedures; and
●
maintaining
continued compliance with the Nasdaq Listing Rules, including compliance with Nasdaq corporate governance requirements.
We
may not be able to integrate, operate, or improve CFO Silvia effectively.
The
integration and operation of CFO Silvia may be difficult and may impose significant demands on management and our administrative and
financial resources. Integration risks include, among others, implementing consistent operating standards; consolidating systems, procedures,
and vendors; integrating management and personnel; retaining key employees; maintaining employee morale; adapting marketing strategies
to local markets; and establishing or enhancing financial reporting systems and internal control over financial reporting. If we are
unable to successfully integrate CFO Silvia, our business, results of operations, and cash flows could be materially adversely affected.
Risks
Related to Ownership of Our Common Stock.
As
a result of the resignation of one of our directors in January 2026, we are not in compliance with Nasdaq rules regarding the composition
of our Board and audit committee, and there is a risk of delisting if the non-compliance is not cured within the time period allowed
by Nasdaq.
On
January 21, 2026, William H. Miller IV resigned from our Board. Mr. Miller was one of three members of the audit committee of our Board.
As a consequence of Mr. Miller’s resignation, we became out of compliance with Nasdaq Listing Rule 5605(c)(2), which requires that
the board of directors of a Nasdaq listed company have an audit committee made up of at least three independent directors. On January
22, 2026, we advised Nasdaq of Mr. Miller’s resignation, its consequences with regard to compliance with Nasdaq Listing Rule 5605(c)(2)
and our intention to regain compliance with Nasdaq Listing Rule 5605(c)(2) in a timely manner. In accordance with Nasdaq Listing Rule
5605(c)(4), we have an automatic cure period in order to regain compliance with Nasdaq Listing Rule 5605(c)(2) until (i) the earlier
of our next annual stockholders’ meeting or January 21, 2027; or (ii) if our next annual stockholders’ meeting is held
before July 20, 2026, then we must evidence compliance no later than July 20, 2026. We intend to appoint a third independent director
to our Board and audit committee and thereby regain compliance with Nasdaq Listing Rule 5605(c)(2), prior to our next annual meeting
of stockholders. However, if we are unable to regain compliance with Nasdaq Listing Rule 5605(c)(2) in a timely manner, Nasdaq will
commence suspension and delisting procedures.
30
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.